<DOC>
	<DOC>NCT02424916</DOC>
	<brief_summary>This study evaluates the safety as well as the potential clinical efficacy of an adoptive transfer of CD8+ T cells, sorted with HLA-peptide multimers and specific for Melan-A and MELOE-1 melanoma antigens, to patients suffering from advanced metastatic melanoma (stages IIIc and IV).</brief_summary>
	<brief_title>Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Male or female ≥ 18 and ≤ 75 years Patient expressing the A2 serotype of the human leukocyte antigen (HLA A2 patient) Patient with metastatic melanoma stage IIIc or IV (AJCC 2010) except brain metastases Tumor expressing the antigens MelanA and MELOE1 detected by RTPCR Absence of cerebral metastases ECOG ≤ 2 or Karnofsky &gt; 80 % Prior adjuvant melanoma treatment (before metastatic stage) authorized (anti BRAF, antiCTLA4, IFN, TIL... ) Disease measurable / evaluable within 28 days before the first administration of study treatment Negative viral serology (HIV 1/2, Ag p24 , HTLV 1/2 , hepatitis B and C, syphilis) Results of analysis: Hemoglobin ≥ 10 g / dl or ≥ 6.25 mmol / l Leukocytes ≥ 4000/μl Lymphocytes ≥ 2000/μl Platelets ≥ 80.000/μl Creatinine ≤ 2.5 N Total bilirubin ≤ 3 N AST and ALT ≤ 3 N without liver metastases; ≤ 5 N with liver metastases Negative pregnancy test for women of childbearing age Patient affiliated to a social security system Patient who has signed informed consent Brain metastases Ocular primitive melanoma Treatment of metastatic melanoma by more than two lines (chemotherapy , immunotherapy, targeted therapy or radiotherapy) or within 4 weeks before the inclusion Treatment with ipilimumab within 8 weeks before the inclusion Known allergy to albumin Contraindication to the use of vasopressors Positive viral serology for HIV 1/2 , Ag p24 , HTLV 1/2, hepatitis B or C, or syphilis Women who are pregnant, nursing or refusing to use contraceptives, women with no negative pregnancy test at baseline Presence of a second active cancer (with the exception of cervical cancer in situ or skin cancer other than melanoma) History of event or current event of a progressive or nonstabilized severe heart disease (congestive heart failure, coronary artery disease, uncontrolled hypertension, serious arrhythmias or ECG signs of previous myocardial infarction) Uncontrolled thyroid dysfunction Any serious acute or chronic illness (active infection requiring antibiotics, bleeding disorders or other condition requiring concomitant treatment not allowed in this study) History of chronic autoimmune disease (Addison's disease, multiple sclerosis, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, ... ) with the exception of patients with active vitiligo or a history of vitiligo History of uveitis and retinopathy associated with melanoma Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Onco-dermatology</keyword>
	<keyword>stage IIIc</keyword>
	<keyword>adoptive transfer</keyword>
	<keyword>immunotherapy</keyword>
</DOC>